vgt-309
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 24, 2022 (NCT05400226)
Timeline
Indications
Mechanism of action
- Cathepsin DINHIBITOR
CTSD inhibitor
- Cathepsin BINHIBITOR
CTSB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06145048 | Phase 2 | Oct 5, 2023 | Vergent Bioscience, Inc. |
| NCT06034197 | Early Phase 1 (Phase 1) | Sep 27, 2023 | Stanford University |
| NCT05400226 | Phase 2 | May 24, 2022 | National Cancer Institute (NCI), Vergent Bioscience, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vergent Bioscience, Inc. | For profit | 2 | 2 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1